In the first quarter, ONC achieved an adjusted earnings per share of $1.22, alongside a revenue of $1.1 billion, which fell short of the expected $1.14 billion. This quarter marked a significant milestone with the company's first GAAP profitable quarter, supported by steady global revenue expansion. In the U.S., the cancer treatment BRUKINSA maintained its dominant position in the initiation of new chronic lymphocytic leukemia (CLL) therapies and emerged as the leader in the overall BTKi market share.
The company is advancing its efforts in late-stage hematology and solid tumor treatments, anticipating several proof-of-concept results throughout the year. These developments include a broad range of innovative therapies such as antibody-drug conjugates, multispecific antibodies, and targeted protein degraders. With growing financial momentum and a strong international presence across six continents, ONC is set to transition to BeOne Medicines and relocate its headquarters to Switzerland, aiming to establish itself as a key player in oncology innovation worldwide.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for BeiGene Ltd (ONC, Financial) is $277.93 with a high estimate of $376.00 and a low estimate of $207.00. The average target implies an upside of 14.97% from the current price of $241.75. More detailed estimate data can be found on the BeiGene Ltd (ONC) Forecast page.
Based on the consensus recommendation from 24 brokerage firms, BeiGene Ltd's (ONC, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for BeiGene Ltd (ONC, Financial) in one year is $549.01, suggesting a upside of 127.1% from the current price of $241.75. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the BeiGene Ltd (ONC) Summary page.
